### NMR LipoProf+Graph

**TESTS** | **RESULT** | **FLAG** | **UNITS** | **REFERENCE INTERVAL** | **LAB**  
---|---|---|---|---|---  
LDL Particle Number | 643 | 01 | nmol/L | <1000 | 01  
LDL-P | 643 | Low | nmol/L | 0 - 1000 | 01  
Moderate | nmol/L | 1000 - 1299 | 01  
Borderline-High | nmol/L | 1300 - 1599 | 01  
High | nmol/L | 1600 - 2000 | 01  
Very High | nmol/L | > 2000 | 01  
Lipids | 77 | 01 | mg/dL | 0 - 99 | 01  
LDL-C | 77 | Optimal | mg/dL | 0 - 100 | 01  
Above optimal | mg/dL | 100 - 129 | 01  
Borderline | mg/dL | 130 - 159 | 01  
High | mg/dL | 160 - 189 | 01  
Very high | mg/dL | > 189 | 01  
Comment: LDL-C is inaccurate if patient is non-fasting.  
HDL-C | 83 | 01 | mg/dL | >39 | 01  
Triglycerides | 57 | 01 | mg/dL | 0 - 149 | 01  
Cholesterol, Total | 171 | 01 | mg/dL | 100 - 199 | 01  
LDL and HDL Particles | 37.7 | 01 | umol/L | >30.5 | 01  
Small LDL-P | 90 | 01 | nmol/L | <=527 | 01  
LDL Size | 21.2 | 01 | mm | >20.5 | 01  

**INTERPRETATIVE INFORMATION**

**PARTICLE CONCENTRATION AND SIZE**

- LDL AND HDL PARTICLES
- Percentile in Reference Population
- HDL-P (total)  
  - High  
  - 75th
  - 50th
  - 25th
  - Low
  - >34.9
  - 34.9
  - 30.5
  - 26.7
  - <26.7

- Small LDL-P  
  - Low  
  - 25th
  - 50th
  - 75th
  - High
  - <117
  - 117
  - 527
  - 839
  - >839

- LDL Size
  - <Large (Pattern A)>
  - <23.0
  - 20.6
  - 20.5
  - 19.0
  - <Small (Pattern B)>
### Insulin Resistance Score

- **Comment:** Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

- **LP-IR Score\(^\text{a}\)**
  - **Flag:** <25
  - **Reference Interval:** <=45

\(^{\text{a}}\) **INSULIN RESISTANCE MARKER**

- **Percentile in Reference Population**
  - Insulin Resistance Score
    - **LP-IR Score**:
      - **Low**:
        - 25th: 27
        - 50th: 45
        - 75th: 63
        - High: >63

- **Comment:** LP-IR Score is inaccurate if patient is non-fasting.
  - The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.

- **NMR PDF Image**

### Comments:

- **This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.**
NMR LipoProfile® test

<table>
<thead>
<tr>
<th>Percentile</th>
<th>20th</th>
<th>Reference Interval¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>nmoL/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL-P</td>
<td>643</td>
<td>&lt; 1000</td>
</tr>
<tr>
<td>(LDL Particle Number)</td>
<td></td>
<td>1000 - 1299</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1300 - 1599</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1600 - 2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt; 2000</td>
</tr>
</tbody>
</table>

Lipids

<table>
<thead>
<tr>
<th>Percentile</th>
<th>50th</th>
<th>80th</th>
<th>95th</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL-C</td>
<td>77</td>
<td>&lt; 100</td>
<td>100 - 129</td>
</tr>
<tr>
<td>(calculated)</td>
<td></td>
<td>130 - 159</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>160 - 189</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt; 190</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Percentile</th>
<th>50th</th>
<th>80th</th>
<th>95th</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-C</td>
<td>83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Desirable ≥ 40)</td>
<td></td>
<td>Triglycerides</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Desirable &lt; 150</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total Cholesterol</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Desirable &lt; 200</td>
<td></td>
</tr>
</tbody>
</table>

LDL-C is inaccurate if patient is non-fasting.

Historical Reporting

<table>
<thead>
<tr>
<th>LDL-P</th>
<th>500</th>
<th>1000</th>
<th>1500</th>
<th>2000</th>
<th>2500</th>
<th>3000</th>
</tr>
</thead>
<tbody>
<tr>
<td>643</td>
<td>643</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LDL-C</th>
<th>50</th>
<th>150</th>
<th>250</th>
<th>350</th>
<th>450</th>
<th>550</th>
</tr>
</thead>
<tbody>
<tr>
<td>77</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

Issued or Pending

PATENTS

CLIA Number

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 800-222-7566.
PARTICLE CONCENTRATION AND SIZE

- LDL and HDL Particles
  - HDL-P (total) 37.7 μmol/L
  - SMALL LDL-P <90 nmol/L
  - LDL SIZE 21.2 nm

Lower CVD Risk
- Percentile in Reference Population:
  - 75th: 34.9
  - 50th: 36.5
  - 25th: 26.7

Higher CVD Risk
- Percentile in Reference Population:
  - 75th: 839
  - 50th: 527
  - 25th: 117

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

Insulin Resistance Score

- Insulin Sensitive
  - Percentile in Reference Population:
    - 25th: 27
    - 50th: 45
    - 75th: 63

- Insulin Resistant

LP-IR Score <25

LP-IR Score is inaccurate if patient is non-fasting.

** The LP-IR score is a laboratory-developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score has not been cleared by the US Food and Drug Administration.

Clinician Notes

- This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

References:
1. Liposkience reference population comprises 4,598 men and women without known CVD or diabetes and not on lipid medication.